Navigation Links
e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
Date:10/20/2009

FERNANDINA BEACH, Fla., Oct. 20 /PRNewswire/ -- e-Zassi.com, the fast-growing provider of the medical device industry's first secure online decision-support and industry network, has released its powerful U.S. Regulatory Calculator as a stand-alone tool available at $375 at www.e-Zassi.com to give users an analysis of the FDA classification of up to three separate medical technologies along with a one-year membership in the e-Zassi medical device industry network.

e-Zassi.com was developed as an online industry network to allow everyone across the spectrum of medical device industry to search, match, collaborate and analyze technologies, individuals and organizations using the most advanced decision-support search engine platform that uniquely fosters deeper levels of information sharing while also protecting members from over-disclosure issues that could negatively impact intellectual properties.

The e-Zassi.com U.S. Regulatory Calculator

The e-Zassi.com U.S. Regulatory Calculator is proprietary software powered by a current database of information on classified medical devices. Anyone involved with medical devices - from researchers to engineers, technology transfer agents, business development officers, medical device companies and investors - can use the new FDA Regulatory Calculator by inputting non-confidential product attributes and physical details about their new product or technology. The e-Zassi.com U.S. Regulatory Calculator searches and provides the potential predicate codes and other critical regulatory information in just minutes, rather than more than two months, which is often how long it takes for the U.S. Food and Drug Administration to determine a product's classification.

"Because many products don't fit neatly into existing classifications, this process is often a complex and confusing first step when designing a product or making a subm
'/>"/>

SOURCE e-Zassi.com
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
(Date:9/2/2015)... -- Elekta, a global cancer management company, will ... 6:30-8:30 p.m., at Elekta,s North American headquarters in ... will feature Professional BMX athlete, Josh Perry , who ... Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain disorders. ... diagnosed in Georgia in 2015 and ...
(Date:9/2/2015)... Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) ... to implement a buccal cannabis co-development arrangement ... has been formalized. Generex and ... and Technology Licensing Agreement.  Pursuant to the ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3
... , , INDIANAPOLIS, Nov. 16 ... Chairman, President and Chief Executive Officer John Lechleiter today presented ... check represents the contributions of Lilly,s U.S. employees and retirees ... funds were raised for the Central Indiana chapter and other ...
... , - Used during coronary angioplasty plus stenting, in ... new reversible blood thinner did not have a significantly ... all-cause mortality, heart attack and need for new procedures ... drug significantly lessened the risk for two pre-specified single ...
Cached Medicine Technology:Lilly Surpasses United Way 2009 Campaign Goal 2Lilly Surpasses United Way 2009 Campaign Goal 3American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
(Date:9/2/2015)... ... 2015 , ... The Western Connecticut Health Network (WCHN) has ... to establish the Abraham and Mildred Goldstein Endowment Fund for Ovarian Cancer Research. ... known gynecologic oncologist Thomas J. Rutherford, MD, PhD as its network physician director ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... data collection, cloud analytics and workflow solutions today announced the September 2015 ... researchers to participate in interactive programs in which ERT scientists and partner ...
(Date:9/2/2015)... Waltham, MA (PRWEB) , ... September 02, 2015 ... ... often get swamped with a large stream of mixed documents that include EOBs, ... the various documents, while extracting the data needed to reconcile their billing, with ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces a ... plus-size actress as the primary love interest in the film. The campaign is being ... significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and CEO ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2
... weight loss drugs are really safe, an analysis of previous ... was conducted. What// came to light was the lack of ... ,Two Canadian researchers, Raj Padwal and Sumit Majumdar of ... like sibutramine (Meridia), orlistat (Xenical) and rimonabant (Acomplia) are no ...
... new proposal released by Gov. Arnold Schwarzenegger recently, workers ... double benefit - to their// health and wealth. Employees ... be exempted from tax. ,The proposal is ... is reachable to the approximate 6.5 million Californians who ...
... towards understanding how the human brain learns to recognize ... of Technology, in 2003 launched a project to study ... Prakash" aims to study, identify and, treat, children who ... a lady born blind was studied by the professor, ...
... India plans to promote the development of public-private partnerships ... the National AIDS Control Programme (NACP-III) is likely to ... that approx. 80 per cent of the Indians seek ... per cent for inpatient care. ,A national ...
... diabetes mellitus (NODM) develops in certain patients following a liver ... to develop//, finds that all the risk factors can be ... tailored to the patient's risk ,They found the ... and hepatitis C infection (HCV) paired with the use of ...
... Prevention (CDC) Atlanta's Division of Tuberculosis Elimination feel that ... made TB tests mandatory for all foreign-born nationals, irrespective ... ,Tuberculosis can only be eradicated if all foreign-born ... treated for latent TB infection, they say. ...
Cached Medicine News:Health News:Latest Research on Visual Skills is an Eye Opener 2Health News:Risk Factors That Cause NODM After A Liver Transplant 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, ... its space saving, 2-level design. Up to 27 ... to give you the flexibility to tailor your ... lab. Two start stations allow for continuous loading; ...
... latest from the leader in automatic slide ... modern approach to slide staining, ending messy ... blood smears, bone marrow and other body ... Aerospray stainer becomes a superb cytocentrifuge with ...
Medicine Products: